{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:26:15Z","timestamp":1792697175578,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clml.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:03:42Z","timestamp":1775495022000},"page":"e853-e867","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5957-3802","authenticated-orcid":false,"given":"Mohammad Ahsen","family":"Soomro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeries","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.04.004_bib0001","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.04.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-024-02404-6","article-title":"LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma \u20132-year follow-up (final analysis)","volume":"38","author":"Mateos","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.04.004_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","author":"Swan","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.004_bib0004","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.04.004_bib0006","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 CAR T-cell therapy","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nature Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0007","article-title":"Identification of T-cell subsets associated with response to BCMA-targeted CAR T-cell therapy in multiple myeloma","volume":"139","author":"Cohen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0008","first-page":"1515","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: US Myeloma Immunotherapy Consortium real-world experience","volume":"109","author":"Hashmi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.04.004_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0010","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T-cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.04.004_bib0011","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.04.004_bib0012","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0013","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/j.clml.2025.09.015","article-title":"Real-world efficacy outcomes of ciltacabtagene autoleucel in relapsed refractory multiple myeloma: a comparative study with the cartitude-1 trial","volume":"26","author":"Kamboj","year":"2026","journal-title":"Clin Lymph Myelom Leuk"},{"key":"10.1016\/j.clml.2026.04.004_bib0014","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2022-168903","article-title":"Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors","volume":"140","author":"Samur","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-025-00643-6","article-title":"Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting","volume":"14","author":"Hu","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib0016","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S1470-2045(18)30576-X","article-title":"Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial","volume":"19","author":"Trudel","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib0017","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies: BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib0044","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","article-title":"CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape","volume":"568","author":"Hamieh","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.clml.2026.04.004_bib0054","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib71","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u0393-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.04.004_bib72","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib73","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone Methyltransferase Ezh2 controls mehanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.clml.2026.04.004_bib75","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41577-019-0195-7","article-title":"Alternative mRNA splicing in cancer immunotherapy","volume":"19","author":"Frankiw","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2026.04.004_bib0018","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2026.04.004_bib0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm.4036","article-title":"Targeting EZH2 in cancer","volume":"22","author":"Kim","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0021","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0022","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2026.04.004_bib0023","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2026.04.004_bib0024","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2026.04.004_bib0025","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.clml.2026.04.004_bib0032","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41591-022-01960-7","article-title":"T cell functional and transcriptional signatures of response to BCMA CAR T-cell therapy in multiple myeloma","volume":"28","author":"Good","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2026.04.004_bib76","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41375-023-02105-6","article-title":"Predictors of early mobility and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase 3 trials and 3700 patients","volume":"38","author":"Mai","year":"2024","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.clml.2026.04.004_bib0048","first-page":"4533","article-title":"Stroma-dependent resistance in multiple myeloma: challenges for CAR T-cell therapy","volume":"29","author":"Das","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.004_bib0026","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.clml.2026.04.004_bib0027","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.clml.2026.04.004_bib0028","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed\/refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0029","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0030","article-title":"CAR T-cell therapy in multiple myeloma: beyond targeting BCMA","author":"Teoh","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib0031","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0033","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cmet.2017.06.016","article-title":"Metabolic regulation of T cell longevity and function in tumor immunotherapy","volume":"26","author":"Kishton","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.clml.2026.04.004_bib0034","article-title":"Metabolic determinants of CAR T-cell dysfunction in multiple myeloma","author":"Kwon","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2026.04.004_bib0035","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","article-title":"Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells","volume":"6","author":"Ghassemi","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"20","key":"10.1016\/j.clml.2026.04.004_bib0039","first-page":"6118","article-title":"Impact of baseline immune composition on outcomes with BCMA CAR T therapy","volume":"6","author":"Mailankody","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.04.004_bib77","doi-asserted-by":"crossref","unstructured":"Jagannath S. Richter J., Dhakal B, et al. Patterns of response to 200 MG Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the Linker-MM1 study. Blood. 2023;1001:142.","DOI":"10.1182\/blood-2023-177968"},{"issue":"685","key":"10.1016\/j.clml.2026.04.004_bib0065","doi-asserted-by":"crossref","first-page":"eabm5663","DOI":"10.1126\/scitranslmed.abm5663","article-title":"Armored CAR T cells enhance function in immunosuppressive niches","volume":"16","author":"Liu","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2024-201194","article-title":"BCMA CART therapy failure in myeloma is associated with immunosuppressive S100A8\/9 overexpression and can be ameliorated with novel monoclonal antibodies","volume":"144","author":"Aleman","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0037","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.04.004_bib0038","first-page":"600","article-title":"The immune microenvironment in multiple myeloma and implications for immunotherapy","volume":"19","author":"Kumar","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"issue":"6","key":"10.1016\/j.clml.2026.04.004_bib0041","first-page":"110","article-title":"Myeloid-derived suppressor cells in multiple myeloma: implications for CAR T-cell therapy","volume":"11","author":"Rose","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2026.04.004_bib0042","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0043","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib0045","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.clml.2026.04.004_bib0046","first-page":"850","article-title":"Cytokine networks in multiple myeloma and their role in immunotherapy resistance","volume":"15","author":"Giannakoulas","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clml.2026.04.004_bib0047","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.004_bib0049","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/ehm.09.55","article-title":"Environmental-mediated drug resistance: a target for multiple myeloma therapy","volume":"2","author":"Shain","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2026.04.004_bib0050","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/vaccines4040046","article-title":"Tumor microenvironment metabolism: a new checkpoint for anti-tumor immunity","volume":"4","author":"Scharping","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.clml.2026.04.004_bib0051","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","article-title":"HIF transcription factors, inflammation, and immunity","volume":"41","author":"Palazon","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.clml.2026.04.004_bib0052","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.clml.2026.04.004_bib0053","doi-asserted-by":"crossref","first-page":"1663814","DOI":"10.3389\/fonc.2025.1663814","article-title":"Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: impact of extramedullary and paramedullary disease","volume":"15","author":"Abuhelwa","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2026.04.004_bib78","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","article-title":"\u0393-Secretase inhibitor in combination with BCMA chiceric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial","volume":"24","author":"Cowan","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.04.004_bib0063","first-page":"24","article-title":"BCMA\u2013CD19 dual-target CAR T-cell therapy prevents antigen escape in multiple myeloma","volume":"17","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.04.004_bib0055","first-page":"811","article-title":"\u03b3-Secretase inhibition enhances BCMA expression and CAR T-cell activity","volume":"24","author":"Cowan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.004_bib0056","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-Targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0057","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1111\/bjh.70116","article-title":"Emerging role of G protein-coupled receptor class C group 5 member d-directed immunotherapy in multiple myeloma: advances, resistance and combination strategies","volume":"207","author":"Wang","year":"2025","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2026.04.004_bib0058","first-page":"142","article-title":"Talquetamab in relapsed\/refractory multiple myeloma","volume":"389","author":"Chari","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.04.004_bib0059","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0060","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1182\/blood-2023-187409","article-title":"Sequential T-cell engagement for Myeloma (\u201cSTEM\u201d) trial: a phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy","volume":"142","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0061","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","article-title":"Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy","volume":"4","author":"Garfall","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2026.04.004_bib0062","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","article-title":"Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial","volume":"11","author":"Zhou","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.04.004_bib0064","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2025-699","article-title":"Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the \u201cSTEM\u201d (Sequential T Cell-Engagement for Myeloma) trial","volume":"146","author":"Cohen","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.04.004_bib0066","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2026.04.004_bib0067","first-page":"4546","article-title":"MRD dynamics and relapse patterns after BCMA-targeted immunotherapy","volume":"29","author":"Paiva","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2026.04.004_bib0068","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3324\/haematol.2023.283831","article-title":"Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients","volume":"109","author":"Mithraprabhu","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.04.004_bib0069","first-page":"1789","article-title":"Cevostamab in relapsed or refractory multiple myeloma","volume":"399","author":"Trudel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.04.004_bib0070","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/hematology.2025000721","article-title":"CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma","volume":"2025","author":"Dima","year":"2025","journal-title":"Hematology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:57:59Z","timestamp":1785239879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":77,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2152265026001047"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resistance to BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma: Biology, Clinical Patterns, and Strategies to Overcome Treatment Failure","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}